New use of blood cleaning device saves high-risk patients with liver failure
(University of Maryland Medical Center) University of Maryland School of Medicine researchers report that a device that removes toxins from the blood can also effectively provide a bridge to liver transplantation or buy time for a traumatically injured liver to heal, suggesting broader uses for the device than previously thought.
Authors: Huang S, Tang Y, Zhu Z, Yang J, Zhang Z, Wang L, Sun C, Zhang Y, Zhao Q, Chen M, Wu L, Wang D, Ju W, Guo Z, He X Abstract BACKGROUND The inherent challenges of selecting an acceptable donor for the increasing number and acuity of recipients has forced programs to take increased risks, including accepting donors with a cancer history (DWCH). Outcomes of organ transplantation using organs from DWCH must be clarified. We assessed transplant outcomes of recipients of organs from DWCH. MATERIAL AND METHODS Retrospective analysis of the Scientific Registry of Transplant Recipients data from January 1, 2000 to De...
CONCLUSION: findings should be interpreted cautiously, due to limited and poor-quality evidence. Rigorously designed further research of the psychosocial interventions targeting predictive demographic variables is recommended. PMID: 29457938 [PubMed - in process]
Condition: Cirrhosis, Liver Intervention: Other: intestinal microbiota transplant Sponsor: Zhongshan Hospital Xiamen University Recruiting
ConclusionsIn our early diagnosed cohort, the 9‐year survival with native liver was better than that reported in other studies. Approximately 15% of patients developed liver‐related disease complications, less than previously reported. The long‐term course of SC was negatively influenced by the presence of autoimmune features, but not by concomitant IBD.
Summary To examine mid‐term benefits on hepatic complications, extrahepatic clinical syndromes and quality of life associated with HCV cure; to review the few safety issues linked to oral direct‐acting antivirals (DAAs); and to discuss the potential population benefits of reducing the burden of HCV infection. DAAs cure HCV infection in more than 95% of patients. The halting of liver inflammation and fibrosis progression translates into both hepatic and extrahepatic benefits and reduces the need for liver transplantation. A reduction in the frequency of extrahepatic manifestations such as mixed cryoglobulinaemia and vas...
ConclusionsPenicillamine followed by zinc may be a safe and effective treatment in resource-constrained setting for symptomatic hepatic WD patients in all grades of baseline disease severity. Some patients with decompensated cirrhosis due to WD may be managed with medical treatment, avoiding liver transplantation.
ConclusionOur experience further highlights the challenges of LTBI screening prior to LT and suggests that QFT may be a poor predictor of active TB in higher risk pre‐transplant populations. Candidates should be screened as early as possible to optimize QFT performance, and local epidemiological data should be used to create institution‐specific screening protocols in areas with large populations from TB‐endemic regions. Management should consider TB risk factors, QFT, and imaging instead of reliance on QFT testing alone.
Conclusions : Sufficient desensitization for ABO-I living donor liver transplantation can be achieved using rituximab alone. This desensitization strategy does not affect the isoagglutinin titers, ABO-I-related complications and patient survival.
Abstract Background: Obesity is increasingly common before and after liver transplantation (LT), yet optimal management remains unclear. Aim: To analyze the long term outcomes for obese patients undergoing LT including a non‐invasive weight loss program and combined LT and sleeve gastrectomy (SG). Methods: Since 2006, all patients referred for LT with a body mass index (BMI) ≥35 kg/m2 were enrolled. Patients who achieved weight loss (BMI 3 years of follow‐up, while overall, a total of 29 patients underwent LT+SG. Patients in the LT cohort had less severe obesity at enrollment (40.0±2.7 vs. LT+SG cohort...